Shots: Caraway to receive ~$267M including $17M up front in cash and remaining as option payment & milestones and is eligible for additional regulatory and commercial milestones along with royalties & gets the option to take part in product development in exchange for higher royalty rates Post pre-clinical research and development activities, AbbVie has an […]Read More
Shots: STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and […]Read More
Shots: Denali to receive $560M up front, $465M as equity investment at a price of $34.94/ share, representing 11.2% of Denali’s Pro-forma outstanding stock along with $1.125B as milestones. The two companies will codevelop Denali’s LRRK2 inhibitor for PD and co-commercialize it in the US and China while Biogen has the right to commercialize the […]Read More
Shots: Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD (formerly OXB-102) to treat mod. to sev. PD based on Oxford’s LentiVector platform Axovant is conducting a P-II SUNRISE-PD trial with AXO-Lenti-PD while the dosing of all patients in the second cohort is completed with 6mos. […]Read More
Shots: The US FDA has granted approval to Nourianz for use as an add-on treatment to levodopa/carbidopa and is based on clinical studies assessing Nourianz vs PBO in PD patients experiencing “OFF” episodes, administering a stable dose of levodopa/carbidopa with/out other PD therapies The four clinical study results demonstrated that adjunct to levodopa/carbidopa, istradefylline improves […]Read More
Shots: The DBS system with the Vercise Cartesia Directional Lead is evaluated in INTREPID study which demonstrated that patients treated with the Vercise System resulted in 48% improvement in motor function as measured by UPDRS III scores for 2yrs. The ImageReady MRI labeling for the Vercise Gevia DBS system used in a full-body MRI of […]Read More
Shots: The agreement collaborates C4XD’s Taxonomy3 (target identification platform) with PhoreMost’s SITESEEKER (screening platform) to accelerate drug discovery initially focusing on Parkinson’s disease with expected profit sharing by both the companies on validated targets The focus of the agreement is to advance C4XD drug discovery pipeline by validating targets identified by C4XD’s Taxonomy3 with the […]Read More
Shots: Hisamitsu to receive upfront, milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000, post marketing approval in Japan The focus of the agreement is to develop & commercialize therapies for Parkinson’s disease developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology […]Read More
Shots: The ongoing AXO-Lenti-PD (also known OXB-102) study evaluates efficacy, safety, tolerability and measuring motor function in patients with PD. The closure of initial results from study is expected in H1’19 The trial is based on results of P-I/II trial of ProSavin for its safety and efficacy, demonstrating reductions in UPDRS Part III “OFF” scores […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
